- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
e-Health ethics code to be finalized in May
There is still time to file comments on the International e-Health Ethics Code, written as a result of the Internet Health Coalition’s Ethics Summit, which took place in early February. According
There is still time to file comments on the International e-Health Ethics Code, written as a result of the Internet Health Coalitions Ethics Summit, which took place in early February. According to Dr. Helga Rippin, IHC chair, approximately 50 sets of comments have been filed as of early April. The proposed code addresses issues like the quality of information offered via the Internet, best commercial practices, and best practices for providing healthcare on the Internet. IHC intends the code to provide guidelines for e-Health and to raise the bar for professional behavior on the Internet. Once the code is final, IHC plans to develop an accreditation or implementation vehicle to ensure that the code is used. According to Rippin, IHC is also working on obtaining formal endorsements for the final document from vendors, government agencies, and special-interest groups all over the world.
IHC started its Internet ethics initiative in response to a challenge issued by Dr. George Lundberg, editor of Medscape, in October 1999. Various entities, including healthcare vendors, dot.coms, consumer groups, and government agencies participated in the summit. IHC issued 50 invitations, 25 by lottery. Following the summit, IHC published the draft code on Feb. 18. The draft code is available on the Web. IHC is accepting comments through the beginning of May.
© 2000 Miller Freeman, Inc., a United News & Media company.
- Search again
- Homepage
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
